The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCTEA.L Regulatory News (CTEA)

  • There is currently no data for CTEA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director and PDMR remuneration - Conversion

27 Jul 2021 07:00

RNS Number : 5128G
Catenae Innovation PLC
27 July 2021
 

27 July 2021

 

Catenae Innovation PLC

("Catenae" or the "Company")

 

Director and PDMR remuneration - Conversion

 

Catenae Innovation PLC (AIM: CTEA), the AIM quoted provider of digital media and technology, announces that the Board has agreed to settle certain existing director and PDMR remuneration liabilities through the conversion of accrued salaries and expenses into new ordinary shares as per the Company's previously stated policy announced on 24 April 2020. The previous conversion of director remuneration into ordinary shares by certain directors was announced on 27 January 2021. The rationale for the conversion into shares is to preserve the existing cash resources of the Company.

 

Guy Meyer and John Farthing, Chief Executive Officer and Chief Financial Officer of the Company respectively, will settle a portion of their remuneration up to 31 August 2021 and will continue receiving shares in lieu of salary on a six month basis.

 

Guy Meyer and John Farthing1 will respectively receive £20,002.20 and £4,702.14 in shares in lieu of payroll liabilities to 31 August 2021 and the Company's Chief Commercial Officer (non-Board role), Nick Delacamp, will receive £1,323.69 in shares to settle expense liabilities up to 31 August 2021 (the "Conversion"). The issue of shares pursuant to the Conversion will be issued at a price equal to the 30-day volume weighted average price per share ("VWAP") to 31 August 2021.

 

Furthermore, following the issue of new ordinary shares, Guy Meyer intends to transfer £20,000 worth of shares received in lieu of remuneration to an ISA account in his name.

 

A further announcement will be made in due course in relation to the issue of new ordinary shares in the Company.

 

1John Farthing's shareholdings are held through Cloisters Capital LLP

 

- Ends -

 

This announcement contains inside information for the purposes of the UK Market Abuse Regulation. The person who arranged for release of this announcement on behalf of the Company was Guy Meyer, Chief Executive Officer of the Company and the Directors of the Company are responsible for the release of this announcement.

 

 

 

For further information please contact:

Catenae Innovation PLC

+44 (0)191 580 8545

Guy Meyer, Chief Executive Officer

 

Cairn Financial Advisers LLP (Nominated Adviser)

+44(0)20 7213 0880

Liam Murray / Jo Turner

 

Brandon Hill Capital Limited, Broker

+44 (0)20 3463 5000

Andy Gutmann

 

 

Yellow Jersey PR (PR & IR)

+44 (0)20 3004 9512

Sarah Hollins / Annabel Atkins / Matthew McHale

 

Notes to Editors:

About Catenae Innovation PLC

Catenae Innovation is an AIM quoted provider of digital media and technology services. Catenae use the power of blockchain to deliver solutions where its people-centric technology enables trust and certainty allowing organisations to gain better control over their operations, manage staff and safely welcome customers.

www.catenaeinnovation.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUNANRANUBUAR
Date   Source Headline
1st Jul 20203:12 pmRNSTotal Voting Rights
1st Jul 20202:06 pmRNSSecond Price Monitoring Extn
1st Jul 20202:00 pmRNSPrice Monitoring Extension
1st Jul 20207:00 amRNSCompletion of Cov-ID Project
30th Jun 20207:01 amRNSHalf-year Report
30th Jun 20207:00 amRNSFinal Results
26th Jun 20204:30 pmRNSExercise of Warrant
23rd Jun 20204:41 pmRNSSecond Price Monitoring Extn
23rd Jun 20204:36 pmRNSPrice Monitoring Extension
19th Jun 20207:00 amRNSCov-ID Project Update
12th Jun 20209:58 amRNSIssue of Equity
11th Jun 20202:02 pmRNSShare Price Movement and Update
10th Jun 202012:30 pmRNSExercise of Warrant, Conversion & Issue of Equity
3rd Jun 20207:00 amRNSHolding(s) in Company
3rd Jun 20207:00 amRNSHolding(s) in Company
3rd Jun 20207:00 amRNSHolding(s) in Company
29th May 202012:24 pmRNSHolding(s) in Company
29th May 20207:00 amRNSAgreement with Newcastle Premier Health Ltd
28th May 20204:41 pmRNSSecond Price Monitoring Extn
28th May 20204:35 pmRNSPrice Monitoring Extension
21st May 20207:00 amRNSExercise of Warrant and Issue of Equity
18th May 20207:00 amRNSCov-ID Project Update
14th May 202012:49 pmRNSResult of General Meeting and Issue of Equity
1st May 20209:00 amRNSUpdate - Cov-ID Project
29th Apr 20205:09 pmRNSPosting of Circular and Notice of General Meeting
28th Apr 20204:41 pmRNSSecond Price Monitoring Extn
28th Apr 20204:35 pmRNSPrice Monitoring Extension
24th Apr 20207:00 amRNSDirectorate Changes
23rd Apr 202012:19 pmRNSHolding(s) in Company
21st Apr 20202:05 pmRNSSecond Price Monitoring Extn
21st Apr 20202:00 pmRNSPrice Monitoring Extension
20th Apr 20203:32 pmRNSConditional Placing to raise £320,000 and Update
17th Apr 20207:00 amRNSCatenae joins Consortium on Cov-ID Project
16th Apr 20205:30 pmRNSChange of Broker
31st Mar 20202:45 pmRNSHolding(s) in Company
31st Mar 20202:40 pmRNSHolding(s) in Company
31st Mar 20202:35 pmRNSHolding(s) in Company
31st Mar 20207:00 amRNSAnnual Report, Trading & COVID-19 Update
26th Mar 202012:49 pmRNSWorking Capital Facility
31st Jan 20201:36 pmRNSIssue of Equity & Proposed Directorate Change
24th Jan 20201:20 pmRNSUpdate re Working Capital & Balance Sheet
10th Jan 202012:23 pmRNSUpdate re Working Capital & Balance Sheet
23rd Dec 201911:37 amRNSResult of General Meeting
20th Dec 20195:02 pmRNSUpdate re Working Capital
20th Dec 20191:23 pmRNSFurther re Share Capital & Timetable Update
20th Dec 20197:00 amRNSShare Capital and Total Voting Rights
19th Dec 20197:00 amRNSFurther re Agreements and update
6th Dec 201910:53 amRNSPosting of Circular and Notice of General Meeting
12th Sep 201910:50 amRNSHolding(s) in Company
11th Sep 20197:30 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.